Primary care doctors raise alarm as telehealth companies get involved in obesity drugs

Primary care doctors raise alarm over telehealth obesity drug use

Primary care doctors raise alarm as telehealth - Primary care doctors raise alarm over the growing role of telehealth companies in managing obesity medications like GLP-1 drugs. As these digital health platforms expand their influence, concerns are mounting about how their cost-cutting strategies may affect patient care and access to essential treatments. The shift has prompted worries among clinicians who fear that streamlined processes could prioritize budgets over personalized medical judgment.

A worker's struggle with a new prescription hurdle

David Davis, a 57-year-old power plant worker near Santa Cruz, Calif., faced a bureaucratic battle with Vida Health to secure his Zepbound prescription. Initially, he had obtained the medication from his primary care physician in December 2025 to address obstructive sleep apnea, which left him exhausted each morning. However, his employer’s new policy required him to use Vida Health’s services, transforming the telehealth platform into a gatekeeper for his treatment. "I thought, 'All right, I'll go through their hoops — I'll jump through their hoops,'” Davis recalled, highlighting the growing pressure on patients to comply with telehealth protocols.

Vida Health, like other telehealth providers, now plays a central role in managing obesity drug access. While they offer lifestyle support for patients on GLP-1s such as Wegovy and Zepbound, their focus has shifted toward reducing costs for employers. Davis submitted updated blood work, detailed health questionnaires, and participated in video consultations with a Vida nurse, only to be asked to try generic alternatives like naltrexone and bupropion. "It was a hassle, but I needed the medication," he said, emphasizing the trade-off between convenience and clinical appropriateness.

Telehealth's evolving role in obesity drug management

Telehealth companies have become increasingly involved in determining who receives obesity medications, according to industry experts. Jayne Hornung, chief clinical officer at MMIT, explained that these services were once used primarily for diabetes prevention but are now capitalizing on the popularity of GLP-1 drugs. "They’ve seen this opportunity in the larger market with the GLP-1s and all the wraparound services they could provide," she said, noting that the trend has "just exploded." Employers, seeking to curb healthcare costs, have embraced these programs as a way to bundle medication with lifestyle interventions.

This approach, while framed as patient-centered, has raised concerns among primary care doctors. They worry that the emphasis on cost efficiency may lead to one-size-fits-all decisions, sidelining the nuanced care required for conditions like sleep apnea. "The endgame is to eventually get the patient healthy, get them on an exercise program, and get them off the GLP-1s," Hornung added. Employers, she said, "don’t want to pay for this forever either." Davis’ experience, though isolated, reflects a broader tension between accessibility and individualized treatment.

Omada Health, another major telehealth provider, has seen significant growth in its obesity drug support programs. Last month, the company reported a 51% increase in membership, now surpassing a million participants. It also highlighted a surge in GLP-1 drug support, with membership rising from over 50,000 in 2024 to more than 150,000 by the end of 2025. "Omada is neither a gatekeeper of GLP-1s nor are we a vending machine," said company President Wei-Li Shao. "And you'll find both extremes of that spectrum out there in the marketplace." This duality allows providers to balance clinical care with cost efficiency, depending on the employer’s priorities.

Industry dynamics and the push for cost efficiency

As telehealth companies grow in influence, they are reshaping how obesity medications are prescribed and administered. These platforms are now key players in employer-driven healthcare strategies, helping to control expenses related to weight-related conditions. Jayne Hornung noted that employers "hired these companies to minimize costs," which has led to a situation where patient outcomes are sometimes secondary to financial considerations. "These companies are hired by employers looking to minimize expenses," she said, underscoring the shift from individualized care to streamlined, cost-effective models.

The integration of telehealth into obesity drug management has sparked debates about its impact on medical autonomy. While some see these services as valuable tools for patient support, others argue that they are overstepping their role by making decisions about medication access. Davis’ case exemplifies this concern, as his ability to obtain Zepbound hinged on navigating a system designed more for